Aflibercept for Age-Related Macular Degeneration

This trial aims to ensure the long-term safety of a treatment called EXG102-031 (also known as Aflibercept) for individuals with neovascular (wet) age-related macular degeneration (nAMD). In nAMD, abnormal blood vessels grow and leak in the eye, causing blurry vision. EXG102-031 is designed to prevent this vessel growth and leakage. Participants who completed a previous study with EXG102-031 and wish to join this follow-up must have been part of the original study and be willing to adhere to the trial's procedures. As a Phase 1 trial, the research focuses on understanding how the treatment works in people.

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.

Research has shown that aflibercept is safe for treating neovascular age-related macular degeneration (nAMD). The FDA has approved it for this use. Studies have found that most patients tolerate aflibercept well. The most common side effects are mild, such as eye pain or redness, while serious side effects are rare. This indicates that aflibercept has a strong safety record for people with nAMD.¹²³⁴⁵

Aflibercept is unique because it targets vascular endothelial growth factor (VEGF), which plays a key role in the abnormal blood vessel growth and leakage that lead to vision loss in age-related macular degeneration (AMD). Unlike other treatments that may require more frequent dosing, aflibercept is designed for longer intervals between injections, potentially offering more convenience for patients. Researchers are excited about aflibercept because it not only inhibits VEGF but also another growth factor involved in the disease process, potentially offering a more comprehensive approach to managing AMD.

Research has shown that aflibercept effectively treats wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels impair vision. Studies such as VIEW 1 and VIEW 2 demonstrated that aflibercept helps manage this condition by reducing fluid build-up and improving vision clarity. It blocks a protein called VEGF, which causes these abnormal vessels to grow. Some research suggests that higher doses of aflibercept may offer additional benefits. Overall, evidence supports aflibercept's ability to improve vision in people with nAMD.¹²⁵⁶⁷